Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients

Contact:

NCT Number:

Protocol:

AAAT7380

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II

The purpose of this study is to find out whether people who are currently receiving treatment with venetoclax can stop treatment and remain off-treatment for at least 12 months, if they are free of residual disease (MRD- negative) when they stop treatment.

Are you Eligible? (Inclusion Criteria)

  • > 18-years-old
  • Diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma confirmed by the enrolling institution
  • Receiving treatment with a venetoclax-based regimen as defined below: - Venetoclax monotherapy (therapy that uses one type of treatment)
  • Venetoclax in combination with anti CD20 monoclonal antibody (Patients must have completed the anti CD20 monoclonal antibody portion of the regimen prior to discontinuing therapy)

Specialty Area(s)

Chronic Lymphocytic Leukemia

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032